Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend

Andras Perl, MD, PhD

SUNY
Syracuse, New York, United States

Andras Perl received his MD and PhD from Semmelweis University in Budapest, Hungary. He was trained in Internal Medicine at Semmelweis and Rheumatology/Immunology at the University of Rochester. He held faculty positions at Semmelweis, the University of Rochester, Roswell Park Memorial Institute, and the State University of New York (SUNY) in Buffalo and Syracuse. He has been Professor of Medicine, Microbiology and Immunology since 1997, SUNY Distinguished Professor since 2017, Chief of Rheumatology since 2001, and Director of the MD/PhD Program since 2004 in Syracuse. His team has identified disease susceptibility genes that regulate mitochondrial homeostasis, autophagy, activation of the mechanistic target of rapamycin pathway, and cell death signal processing in mouse models and patients with autoimmunity, cancer, metabolic diseases. He has initiated and carried out successful clinical trials in patients with systemic lupus erythematosus (SLE), a potentially fatal autoimmune disease of unknown origin. His team has introduced two new treatments for SLE, blocking the activation of the mechanistic target of rapamycin with N-acetylcysteine (Arthritis Rheum 2012) or sirolimus in the context of FDA-approved clinical trials (Lancet 2018). He has published over 200 original peer-reviewed papers in leading medical and scientific journals, authored chapters in rheumatology and immunology textbooks, trained over 70 MD/PhD and PhD students and postdoctoral and rheumatology fellows.

Presentation(s):